Citations Citations to this article as recorded by Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research Xinyi Lu, Li Yang Frontiers in Medicine .2026;[Epub] CrossRef 7,871 View 228 Download 2 Web of Science Crossref Special Issue Steatotic liver disease KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL) Clin Mol Hepatol 2025;31(Suppl):S1-S31
Especially, the elasticity of sun-exposed right face of those who received GSSG was notably higher than the elasticity of those who received placebo ( P = 0.082)
The role of the basal ganglia in habit formation
Montes M, Nielsen MM, Maglieri G, Jacobsen A, Hojfeldt J, Agrawal-Singh S et al
What we do know from the switching protocols published by various clinical practices is that starting low and titrating up works better than trying to jump to an "equivalent" dose
